Target Name: OR1Q1
NCBI ID: G158131
Review Report on OR1Q1 Target / Biomarker Content of Review Report on OR1Q1 Target / Biomarker
OR1Q1
Other Name(s): TPCR106 | Olfactory receptor family 1 subfamily Q member 1 | olfactory receptor 1Q2 | Olfactory receptor 1Q1 | Olfactory receptor OR9-25 | OR9-A | OST226OR9-A | OR1Q3 | OR1Q2 | olfactory receptor 1Q3 | Olfactory receptor TPCR106 | Olfactory receptor 1Q2 | OR9-25 | HSTPCR106 | OST226 | OTTHUMP00000022060 | olfactory receptor TPCR106 | Olfactory receptor 1Q3 | Olfactory receptor, family 1, subfamily Q, member 2 | olfactory receptor, family 1, subfamily Q, member 3 | Olfactory receptor, family 1, subfamily Q, member 3 | Olfactory receptor, family 1, subfamily Q, member 1 | olfactory receptor family 1 subfamily Q member 1 | olfactory receptor OR9-25 | Olfactory receptor 9-A | olfactory receptor, family 1, subfamily Q, member 2 | OR1Q1_HUMAN | olfactory receptor 9-A

OR1Q1: A Promising Drug Target and Biomarker

OR1Q1 (TPCR106) is a drug target and a potential biomarker for the treatment of various diseases, including cancer. Its unique structure and function make it an attractive target for researchers to study.

OR1Q1 is a short non-coding RNA molecule that is expressed in various tissues and cells, including the brain, heart, liver, and muscle. Its function is not well understood, but it is known to play a role in the regulation of gene expression. OR1Q1 has been shown to interact with several proteins, including the transcription factor NF-kappa-B.

One of the main research efforts on OR1Q1 is its potential as a drug target. Many diseases are treated by drugs that inhibit the activity of protein kinases, which are involved in the regulation of cellular processes. OR1Q1 has been shown to be a potential target for such drugs. Several studies have shown that inhibiting the activity of OR1Q1 using small molecules or antibodies can inhibit the activity of NF-kappa-B, which is a transcription factor that plays a role in the regulation of gene expression.

Another potential use of OR1Q1 as a drug target is its potential as a biomarker. The expression of OR1Q1 is regulated by several factors, including gene expression, post-transcriptional modification, and protein-protein interactions. Therefore, changes in the expression of OR1Q1 could be an indication of certain diseases. Several studies have shown that changes in the expression of OR1Q1 are associated with several diseases, including cancer. For example, studies have shown that OR1Q1 is downregulated in various types of cancer, and that inhibition of its expression can lead to the regression of these diseases.

In addition to its potential as a drug target and biomarker, OR1Q1 is also of interest due to its unique structure. OR1Q1 is a short RNA molecule that consists of only 19 amino acid residues. This shortness is unusual for a RNA molecule, and it is not known of any other RNA molecule with such a short length. The small size of OR1Q1 makes it easy to study its properties and interactions with other molecules.

Overall, OR1Q1 is a promising drug target and biomarker for the treatment of various diseases. Its unique structure and function make it an attractive target for researchers to study, and its potential as a drug and biomarker make it a valuable tool for the development of new therapies. Further research is needed to fully understand its properties and its potential as a therapeutic agent.

Protein Name: Olfactory Receptor Family 1 Subfamily Q Member 1

Functions: Odorant receptor

The "OR1Q1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR1Q1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OR1S1 | OR1S2 | OR2A1 | OR2A1-AS1 | OR2A12 | OR2A14 | OR2A2 | OR2A20P | OR2A25 | OR2A4 | OR2A42 | OR2A7 | OR2A9P | OR2AE1 | OR2AG1 | OR2AG2 | OR2AJ1 | OR2AK2 | OR2AL1P | OR2AM1P | OR2AP1 | OR2AT4 | OR2B11 | OR2B2 | OR2B3 | OR2B6 | OR2C1 | OR2C3 | OR2D2 | OR2D3 | OR2F1 | OR2F2 | OR2G2 | OR2G3 | OR2G6 | OR2H1 | OR2H2 | OR2I1P | OR2J1 | OR2J2 | OR2J3 | OR2J4P | OR2K2 | OR2L13 | OR2L1P | OR2L2 | OR2L3 | OR2L5 | OR2L8 | OR2L9P | OR2M1P | OR2M2 | OR2M3 | OR2M4 | OR2M5 | OR2M7 | OR2Q1P | OR2S2 | OR2T1 | OR2T10 | OR2T11 | OR2T12 | OR2T2 | OR2T27 | OR2T29 | OR2T3 | OR2T33 | OR2T34 | OR2T35 | OR2T4 | OR2T5 | OR2T6 | OR2T7 | OR2T8 | OR2U1P | OR2V1 | OR2V2 | OR2W1 | OR2W1-AS1 | OR2W3 | OR2W5P | OR2W6P | OR2Y1 | OR2Z1 | OR3A1 | OR3A2 | OR3A3 | OR3A4P | OR4A14P | OR4A15 | OR4A16 | OR4A17P | OR4A21P | OR4A47 | OR4A5 | OR4B1 | OR4C11 | OR4C12 | OR4C13 | OR4C15